{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:20:15Z","timestamp":1773274815958,"version":"3.50.1"},"reference-count":25,"publisher":"Bentham Science Publishers Ltd.","issue":"7","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCHTS"],"published-print":{"date-parts":[[2019,12,3]]},"abstract":"<jats:sec>\n<jats:title>Aim and Objective:<\/jats:title>\n<jats:p>Mantle Cell Lymphoma (MCL) is typically an aggressive and rare\ndisease with poor prognosis, therefore new effective therapeutics are urgently needed. Drug\nrepurposing for cancer treatment is becoming increasingly more attractive as an alternative\napproach to discover clinically approved drugs that demonstrate antineoplastic effect. The\nobjective of this study was to screen an approved drug library and identify candidate compounds\nwith an antineoplastic effect in MCL cells using High-Throughput Screening (HTS) technique.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Materials and Methods:<\/jats:title>\n<jats:p>Using the HTS technique, nearly 3,800 clinically approved drugs and\ndrug candidates were screened in Jeko and Mino MCL cell lines. We also demonstrated the\nselectivity window of the candidate compounds in six normal cell lines. Further validations were\nperformed in caspase-3\/7 apoptosis assay and three-dimensional (3D) multicellular aggregates\nmodel using Z138 cell line.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>We identified 98 compounds showing &gt;50% inhibition in either MCL cell line screened,\nthey were distributed across eight unique therapeutic categories and have different mechanisms of\naction (MOA). We selected alisertib, carfilzomib, pracinostat and YM155 for further validation\nbased on their antiproliferative activity in two MCL cell lines, selectivity to normal cell lines, and\ndrug developing stages in terms of clinical research. Alisertib and carfilzomib showed\nantiproliferative effect on MCL cell with EC50 = 6 nM and &gt;100-fold selectivity to normal cell\nlines, especially for alisertib which demonstrated &gt;1000-fold selectivity to 5 out of 6 normal cell\nlines. Pracinostat and YM155 had potency of 11 and 12 nM in MCL cell with &gt;20-fold selectivity\nto normal cell lines. All four compounds had been tested in caspase-dependent apoptosis assay. We\nfurther validated and demonstrated their anti-MCL effect on cell proliferation and (3D)\nmulticellular aggregates model using Z138 cell line.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>This is the first study to examine such a large library of clinically approved\ncompounds for the identification of novel drug candidates for MCL treatment, the results could be\nrapidly translated into clinical practice in patients with MCL.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1386207322666190916120128","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T02:50:52Z","timestamp":1568688652000},"page":"483-495","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Drug Repurposing Screen Identifies Novel Classes of Drugs with Anticancer Activity in Mantle Cell Lymphoma"],"prefix":"10.2174","volume":"22","author":[{"given":"Chengwu","family":"Han","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, China-Japan Friendship Hospital, Beijing 100029, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueying","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, China-Japan Friendship Hospital, Beijing 100029, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, China-Japan Friendship Hospital, Beijing 100029, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, China-Japan Friendship Hospital, Beijing 100029, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongyue","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, China-Japan Friendship Hospital, Beijing 100029, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sijie","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, China-Japan Friendship Hospital, Beijing 100029, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, China-Japan Friendship Hospital, Beijing 100029, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"44","volume":"13","author":"Skarbnik A.P.","year":"2015","unstructured":"Skarbnik A.P.; Goy A.H.; Mantle cell lymphoma: State of the art. Clin Adv Hematol Oncol 2015,13(1),44-55","journal-title":"Clin Adv Hematol Oncol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/2040620717719616","volume":"8","author":"Fakhri B.","year":"2017","unstructured":"Fakhri B.; Kahl B.; Current and emerging treatment options for mantle cell lymphoma. Ther Adv Hematol 2017,8(8),223-234","journal-title":"Ther Adv Hematol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/2040620714561579","volume":"6","author":"Rajabi B.","year":"2015","unstructured":"Rajabi B.; Sweetenham J.W.; Mantle cell lymphoma: Observation to transplantation. Ther Adv Hematol 2015,6(1),37-48","journal-title":"Ther Adv Hematol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13045-018-0556-x","volume":"11","author":"Steiner R.E.","year":"2018","unstructured":"Steiner R.E.; Romaguera J.; Wang M.; Current trials for frontline therapy of mantle cell lymphoma. J Hematol Oncol 2018,11(1),13","journal-title":"J Hematol Oncol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/2040620716648566","volume":"7","author":"Hambley B.","year":"2016","unstructured":"Hambley B.; Caimi P.F.; William B.M.; Bortezomib for the treatment of mantle cell lymphoma: An update. Ther Adv Hematol 2016,7(4),196-208","journal-title":"Ther Adv Hematol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/2040620715592569","volume":"6","author":"Stephens D.M.","year":"2015","unstructured":"Stephens D.M.; Spurgeon S.E.; Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion. Ther Adv Hematol 2015,6(5),242-252","journal-title":"Ther Adv Hematol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2017.05.008","volume":"58","author":"Martin P.","year":"2017","unstructured":"Martin P.; Ghione P.; Dreyling M.; Mantle cell lymphoma - Current standards of care and future directions. Cancer Treat Rev 2017,58,51-60","journal-title":"Cancer Treat Rev"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood-2014-05-521898","volume":"125","author":"Campo E.","year":"2015","unstructured":"Campo E.; Rule S.; Mantle cell lymphoma: Evolving management strategies. Blood 2015,125(1),48-55","journal-title":"Blood"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s00277-015-2412-1","volume":"94","author":"McCabe B.","year":"2015","unstructured":"McCabe B.; Liberante F.; Mills K.I.; Repurposing medicinal compounds for blood cancer treatment. Ann Hematol 2015,94(8),1267-1276","journal-title":"Ann Hematol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1111\/j.1349-7006.2010.01723.x","volume":"101","author":"Ho W.J.","year":"2010","unstructured":"Ho W.J.; Pham E.A.; Kim J.W.; Ng C.W.; Kim J.H.; Kamei D.T.; Wu B.M.; Incorporation of multicellular spheroids into 3-D polymeric scaffolds provides an improved tumor model for screening anticancer drugs. Cancer Sci 2010,101(12),2637-2643","journal-title":"Cancer Sci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/jnci\/djm135","volume":"99","author":"Tr\u00e9dan O.","year":"2007","unstructured":"Tr\u00e9dan O.; Galmarini C.M.; Patel K.; Tannock I.F.; Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007,99(19),1441-1454","journal-title":"J Natl Cancer Inst"},{"key":"ref=12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039556","volume":"7","author":"Kim H.","year":"2012","unstructured":"Kim H.; Phung Y.; Ho M.; Changes in global gene expression associated with 3D structure of tumors: An ex vivo matrix-free mesothelioma spheroid model. PLoS One 2012,7(6)","journal-title":"PLoS One"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"7614","DOI":"10.1158\/1078-0432.CCR-11-1536","volume":"17","author":"Manfredi M.G.","year":"2011","unstructured":"Manfredi M.G.; Ecsedy J.A.; Chakravarty A.; Silverman L.; Zhang M.; Hoar K.M.; Stroud S.G.; Chen W.; Shinde V.; Huck J.J.; Wysong D.R.; Janowick D.A.; Hyer M.L.; Leroy P.J.; Gershman R.E.; Silva M.D.; Germanos M.S.; Bolen J.B.; Claiborne C.F.; Sells T.B.; Characterization of alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res 2011,17(24),7614-7624","journal-title":"Clin Cancer Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1182\/blood-2009-12-259523","volume":"115","author":"G\u00f6rg\u00fcn G.","year":"2010","unstructured":"G\u00f6rg\u00fcn G.; Calabrese E.; Hideshima T.; Ecsedy J.; Perrone G.; Mani M.; Ikeda H.; Bianchi G.; Hu Y.; Cirstea D.; Santo L.; Tai Y.T.; Nahar S.; Zheng M.; Bandi M.; Carrasco R.D.; Raje N.; Munshi N.; Richardson P.; Anderson K.C.; A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 2010,115(25),5202-5213","journal-title":"Blood"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/13543784.2018.1417382","volume":"27","author":"Liewer S.","year":"2018","unstructured":"Liewer S.; Huddleston A.; Alisertib: A review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors. Expert Opin Investig Drugs 2018,27(1),105-112","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/CE.S13838","volume":"6","author":"Jain S.","year":"2011","unstructured":"Jain S.; Diefenbach C.; Zain J.; O\u2019Connor O.A.; Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma. Core Evid 2011,6,43-57","journal-title":"Core Evid"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1158\/1078-0432.CCR-09-2882","volume":"16","author":"Wright J.J.","year":"2010","unstructured":"Wright J.J.; Combination therapy of bortezomib with novel targeted agents: An emerging treatment strategy. Clin Cancer Res 2010,16(16),4094-4104","journal-title":"Clin Cancer Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","volume":"67","author":"Demo S.D.","year":"2007","unstructured":"Demo S.D.; Kirk C.J.; Aujay M.A.; Buchholz T.J.; Dajee M.; Ho M.N.; Jiang J.; Laidig G.J.; Lewis E.R.; Parlati F.; Shenk K.D.; Smyth M.S.; Sun C.M.; Vallone M.K.; Woo T.M.; Molineaux C.J.; Bennett M.K.; Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007,67(13),6383-6391","journal-title":"Cancer Res"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1158\/1535-7163.MCT-09-0689","volume":"9","author":"Novotny-Diermayr V.","year":"2010","unstructured":"Novotny-Diermayr V.; Sangthongpitag K.; Hu C.Y.; Wu X.; Sausgruber N.; Yeo P.; Greicius G.; Pettersson S.; Liang A.L.; Loh Y.K.; Bonday Z.; Goh K.C.; Hentze H.; Hart S.; Wang H.; Ethirajulu K.; Wood J.M.; SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther 2010,9(3),642-652","journal-title":"Mol Cancer Ther"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.3109\/13880209.2015.1135966","volume":"54","author":"Ganai S.A.","year":"2016","unstructured":"Ganai S.A.; Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance. Pharm Biol 2016,54(9),1926-1935","journal-title":"Pharm Biol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3390\/ijms18071414","volume":"18","author":"Eckschlager T.","year":"2017","unstructured":"Eckschlager T.; Plch J.; Stiborova M.; Hrabeta J.; Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci 2017,18(7),1414","journal-title":"Int J Mol Sci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ctrv.2009.05.003","volume":"35","author":"Ryan B.M.","year":"2009","unstructured":"Ryan B.M.; O\u2019Donovan N.; Duffy M.J.; Survivin: A new target for anti-cancer therapy. Cancer Treat Rev 2009,35(7),553-562","journal-title":"Cancer Treat Rev"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1002\/cncr.26510","volume":"118","author":"Cheson B.D.","year":"2012","unstructured":"Cheson B.D.; Bartlett N.L.; Vose J.M.; Lopez-Hernandez A.; Seiz A.L.; Keating A.T.; Shamsili S.; Papadopoulos K.P.; A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer 2012,118(12),3128-3134","journal-title":"Cancer"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"8014","DOI":"10.1158\/0008-5472.CAN-07-1343","volume":"67","author":"Nakahara T.","year":"2007","unstructured":"Nakahara T.; Kita A.; Yamanaka K.; Mori M.; Amino N.; Takeuchi M.; Tominaga F.; Hatakeyama S.; Kinoyama I.; Matsuhisa A.; Kudoh M.; Sasamata M.; YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007,67(17),8014-8021","journal-title":"Cancer Res"},{"key":"ref=25","first-page":"206","volume":"174","author":"Cohen J.L.","year":"1970","unstructured":"Cohen J.L.; Jao J.Y.; Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat. J Pharmacol Exp Ther 1970,174(2),206-210","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Combinatorial Chemistry &amp; High Throughput Screening"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/174888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T09:34:27Z","timestamp":1577180067000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/174888\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,3]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,12,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1386207322666190916120128","relation":{},"ISSN":["1386-2073"],"issn-type":[{"value":"1386-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-05-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}